Tumor slice culture system to assess drug response of primary breast cancer
Kishan A T Naipal, Nicole S Verkaik, Humberto Sánchez, Carolien H M van Deurzen, Michael A den Bakker, Jan H J Hoeijmakers, Roland Kanaar, Maaike P G Vreeswijk, Agnes Jager, Dik C van Gent, Kishan A T Naipal, Nicole S Verkaik, Humberto Sánchez, Carolien H M van Deurzen, Michael A den Bakker, Jan H J Hoeijmakers, Roland Kanaar, Maaike P G Vreeswijk, Agnes Jager, Dik C van Gent
Abstract
Background: The high incidence of breast cancer has sparked the development of novel targeted and personalized therapies. Personalization of cancer treatment requires reliable prediction of chemotherapy responses in individual patients. Effective selection can prevent unnecessary treatment that would mainly result in the unwanted side effects of the therapy. This selection can be facilitated by characterization of individual tumors using robust and specific functional assays, which requires development of powerful ex vivo culture systems and procedures to analyze the response to treatment.
Methods: We optimized culture methods for primary breast tumor samples that allowed propagation of tissue ex vivo. We combined several tissue culture strategies, including defined tissue slicing technology, growth medium optimization and use of a rotating platform to increase nutrient exchange.
Results: We could maintain tissue cultures for at least 7 days without losing tissue morphology, viability or cell proliferation. We also developed methods to determine the cytotoxic response of individual tumors to the chemotherapeutic treatment FAC (5-FU, Adriamycin [Doxorubicin] and Cyclophosphamide). Using this tool we designated tumors as sensitive or resistant and distinguished a clinically proven resistant tumor from other tumors.
Conclusion: This method defines conditions that allow ex vivo testing of individual tumor responses to anti-cancer drugs and therefore might improve personalization of breast cancer treatment.
Figures
References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107.
- Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003;64(4):289–99. doi: 10.1159/000070284.
- Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe? Breast Cancer Res. 2003;5(2):89–95. doi: 10.1186/bcr577.
- Seifert HH, Meyer A, Cronauer MV, Hatina J, Muller M, Rieder H, et al. A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol. 2007;25(3):297–302. doi: 10.1007/s00345-007-0166-7.
- Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology. 2011;141(5):1762–72. doi: 10.1053/j.gastro.2011.07.050.
- Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010;107(18):8352–6. doi: 10.1073/pnas.0907676107.
- Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013. doi: 10.1158/-14-0001.
- Failli A, Consolini R, Legitimo A, Spisni R, Castagna M, Romanini A, et al. The challenge of culturing human colorectal tumor cells: establishment of a cell culture model by the comparison of different methodological approaches. Tumori. 2009;95(3):343–7.
- Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, et al. Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer. 1998;78(11):1421–9. doi: 10.1038/bjc.1998.702.
- Dairkee SH, Deng G, Stampfer MR, Waldman FM, Smith HS. Selective cell culture of primary breast carcinoma. Cancer Res. 1995;55(12):2516–9.
- Fiebig HH, Neumann HA, Henss H, Koch H, Kaiser D, Arnold H. Development of three human small cell lung cancer models in nude mice. Recent Results Cancer Res. 1985;97:77–86. doi: 10.1007/978-3-642-82372-5_8.
- Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res. 1982;42(2):535–9.
- Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer. 2014;110(2):479–88. doi: 10.1038/bjc.2013.700.
- Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, et al. Functional ex vivo assay to select Homologous Recombination deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. 2014;20(18):4816–26. doi: 10.1158/1078-0432.CCR-14-0571.
- van der Kuip H, Murdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer. 2006;6:86. doi: 10.1186/1471-2407-6-86.
- Holliday DL, Moss MA, Pollock S, Lane S, Shaaban AM, Millican-Slater R, et al. The practicalities of using tissue slices as preclinical organotypic breast cancer models. J Clin Pathol. 2013;66(3):253–5. doi: 10.1136/jclinpath-2012-201147.
- Sanchez H, Wyman C. SFMetrics: an analysis tool for scanning force microscopy images of biomolecules. BMC Bioinformatics. 2015;16:27. doi: 10.1186/s12859-015-0457-8.
- Manders EMM, Verbeek FJ, Aten JA. Measurement of co-localization of objects in dual-colour confocal images. J Microsc. 1993;169(3):375–82. doi: 10.1111/j.1365-2818.1993.tb03313.x.
- Garvin S, Nilsson UW, Huss FR, Kratz G, Dabrosin C. Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res. 2006;325(2):245–51. doi: 10.1007/s00441-006-0159-7.
- Pennington K, Chu QD, Curiel DT, Li BD, Mathis JM. The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses. J Surg Res. 2010;163(2):270–5. doi: 10.1016/j.jss.2010.03.072.
- Martin M, Ruiz A, Ruiz Borrego M, Barnadas A, Gonzalez S, Calvo L, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013;31(20):2593–9. doi: 10.1200/JCO.2012.46.9841.
- Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–7. doi: 10.1016/S0960-9776(03)00106-1.
- van Oijen MG, Medema RH, Slootweg PJ, Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol. 1998;110(1):24–31.
- Balmativola D, Marchio C, Maule M, Chiusa L, Annaratone L, Maletta F, et al. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat. 2014;148(3):511–23. doi: 10.1007/s10549-014-3192-3.
- Akhtar MS, Kousar F, Masood M, Fatimi S, Kokab Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer. J Coll Physicians Surg Pak. 2010;20(11):748–52.
- Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK, Sharma DN. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev. 2014;15(5):1989–92. doi: 10.7314/APJCP.2014.15.5.1989.
Source: PubMed